Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for MK-3475

5 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMEL16138

    09/08/2017

    A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    ECOGBRES1418

    03/17/2017

    A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN+) After Neoadjuvant Chemotherapy

    Treatment

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

    Treatment

    VICCPED1620

    12/08/2016

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma


    Print this page for your doctor